Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein

被引:93
|
作者
Shao, Baohai
Oda, Michael N.
Oram, John F.
Heinecke, Jay W.
机构
[1] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA
[2] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA
关键词
atherosclerosis; dysfunctional HDL; myeloperoxidase; oxidation; oxidative stress;
D O I
10.1097/01.hco.0000231402.87232.aa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Evidence indicates that high density lipoprotein (HDL) is cardioprotective and that several mechanisms are involved. One important pathway is a membrane-associated ATP-binding cassette transporter, ABCA1, that clears cholesterol from macrophage foam cells. Anti-inflammatory and antioxidant properties also might contribute to HDL's ability to inhibit atherosclerosis. Recent findings Myeloperoxidase targets HDL for oxidation, raising the possibility that the enzyme provides a specific mechanism for generating dysfunctional HDL in humans. Myeloperoxidase-dependent oxidation of apolipoprotein A-I, the major protein in HDL, blocks HDL's ability to remove excess cholesterol from cells by the ABCA1 pathway. Analysis of mutated forms of apoA-I and oxidized apoA-I treated with methionine sulfoxide reductase implicate oxidation of specific tyrosine and methionine residues in impairing the ABCA1 transport activity of apoA-I. The crystal structure of lipid-free apoA-I suggests that such oxidative damage might disrupt negatively charged regions on the protein's surface or alter its remodeling, resulting in conformations that fail to interact with ABCA1. Summary Oxidation of HDL by myeloperoxidase may represent a specific molecular mechanism for converting the cardioprotective lipoprotein into a dysfunctional form, raising the possibility that the enzyme represents a potential therapeutic target for preventing vascular disease in humans. Moreover, oxidized HDL might prove useful as a blood marker for clinically significant cardiovascular disease in humans.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 50 条
  • [21] Low-Density Lipoprotein Modified by Myeloperoxidase in Inflammatory Pathways and Clinical Studies
    Delporte, Cedric
    Van Antwerpen, Pierre
    Vanhamme, Luc
    Roumeguere, Thierry
    Boudjeltia, Karim Zouaoui
    MEDIATORS OF INFLAMMATION, 2013, 2013
  • [22] Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease
    Haraguchi, Yoko
    Toh, Ryuji
    Hasokawa, Minoru
    Nakajima, Hideto
    Honjo, Tomoyuki
    Otsui, Kazunori
    Mori, Kenta
    Miyamoto-Sasaki, Maki
    Shinohara, Masakazu
    Nishimura, Kunihiro
    Ishida, Tatsuro
    Hirata, Ken-ichi
    ATHEROSCLEROSIS, 2014, 234 (02) : 288 - 294
  • [23] High Density Lipoprotein To Macrophage Free Cholesterol Influx And Transfer To Low Density Lipoprotein - New Assays For Dysfunctional High Density Lipoprotein: The Houston Heart Study
    Gillard, Baiba K.
    Yelamanchili, Dedipya
    Saleem, Hira
    Gotto, Antonio M.
    Remaley, Alan
    Rosales, Corina
    Pownall, Henry J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44
  • [24] Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics
    Salazar, Juan
    Olivar, Luis Carlos
    Ramos, Eduardo
    Chavez-Castillo, Mervin
    Rojas, Joselyn
    Bermudez, Valmore
    CHOLESTEROL, 2015,
  • [25] Myeloperoxidase Targets Apolipoprotein A-I for Site-Specific Tyrosine Chlorination in Atherosclerotic Lesions and Generates Dysfunctional High-Density Lipoprotein
    Jin, Zelong
    Zhou, Lan
    Tian, Rong
    Lu, Naihao
    CHEMICAL RESEARCH IN TOXICOLOGY, 2021, 34 (06) : 1672 - 1680
  • [26] Dysfunctional antioxidant capacity of high-density lipoprotein in rheumatoid arthritis
    Garcia-Gomez, Maria Carmen
    Padro, Teresa
    Munoz-Garcia, Natalia
    Bianchi, Maria
    Alvarez, Lorenzo
    Badimon, Lina
    Corbella, Emili
    Pinto, Xavier
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (08)
  • [27] A RAPID EVALUATION MODEL FOR INFLAMMATORY DEATH USING ZEBRAFISH LARVAE BY OXIDIZED LOW-DENSITY LIPOPROTEIN AND DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS
    Park, J.
    Park, K-H.
    Cho, K. -H.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 52 - 52
  • [28] Dysfunctional high density lipoprotein contributes to preclinical atherosclerosis in primary antiphospholipid syndrome
    Charakida, M.
    Besler, C.
    Batuca, J.
    Sangle, S.
    Alves, D. J.
    Mackworth-Young, C.
    Cruz, D.
    Luscher, T.
    Landmesser, U.
    Deanfield, J. E.
    EUROPEAN HEART JOURNAL, 2009, 30 : 960 - 960
  • [29] Evaluation of Dysfunctional High-Density Lipoprotein in Patients With Type 2 Diabetes
    Murakami, Hiroshi
    Matsumura, Koki
    Yamashita, Maki
    Matsuki, Kota
    Tanabe, Jutaro
    Murakami, Hiroshi
    Matsui, Jun
    Tamasawa, Naoki
    Suda, Toshihiro
    DIABETES, 2012, 61 : A129 - A129
  • [30] Dysfunctional high-density lipoprotein: not only quantity but first of all quality?
    Agouridis, Aris P.
    Banach, Maciej
    Mikhailidis, Dimitri P.
    ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) : 230 - 231